C 940
Alternative Names: C-940Latest Information Update: 22 May 2024
At a glance
- Originator RaeSedo
- Class Anti-inflammatories; Antiasthmatics; Peptidomimetics
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Asthma
Most Recent Events
- 15 May 2024 C 940 is available for licensing as of 15 May 2024. https://raesedoinc.com/about-us/
- 15 May 2024 Preclinical trials in Asthma in USA (Inhalation), prior to May 2024
- 15 May 2024 RaeSedo announces intention to submit an Investigational New Drug application with the US FDA for Asthma in the first half of 2025